Abstract:Unhealthy lifestyle habits including a sedentary life, the lack of physical activity, and wrong dietary habits are the major ones responsible for the constant increase of obesity and metabolic disorders prevalence worldwide; therefore, the scientific community pays significant attention to the pharmacotherapy of such diseases, beyond lifestyle interventions, the use of medical devices, and surgical approaches. The intricate interplay between autophagy and inflammation appears crucial to orchestrate fundamental aspects of cellular and organismal responses to challenging stimuli, including metabolic insults; hence, when these two processes are dysregulated (enhanced or suppressed) they produce pathologic effects. The present review summarizes the existing literature reporting the intricate affair between autophagy and inflammation in the context of metabolic disorders, including obesity, diabetes, and liver metabolic diseases (non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)). The evidence collected so far suggests that an alteration of autophagy might lead to maladaptive metabolic and inflammatory responses thus exacerbating the severity of the disease, and the most prominent conclusion underlies that autophagy might exert a protective function by contributing to balance inflammation. However, the complex nature of obesity and metabolic disorders might represent a limit of the studies; indeed, although many pharmacological treatments, producing positive metabolic effects, are also able to modulate autophagic flux and inflammation, it is not clear if the final beneficial effect might occur only by their mechanism of action, rather than because of additionally involved pathways. Finally, although future studies are needed, the observation that anti-obesity and antidiabetic drugs already on the market, including incretin mimetic agents, facilitate autophagy by dampening inflammation, strongly contributes to the idea that autophagy might represent a druggable system for the development of novel pharmacological tools that might represent an attractive strategy for the treatment of obesity and metabolic disorders.

Autophagy and Mitochondria in Obesity and Type 2 Diabetes

Dysregulated autophagy: A key player in the pathophysiology of type 2 diabetes and its complications

Autophagy and Obesity and Diabetes.

Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells.

Role of autophagy in the progression from obesity to diabetes and in the control of energy balance

Autophagy-nutrient sensing pathways in diabetic complications

Autophagy modulators in type 2 diabetes: A new perspective

Autophagy and Its Link to Type II Diabetes Mellitus

The role of autophagy in insulin resistance and glucolipid metabolism and potential use of autophagy modulating natural products in the treatment of type 2 diabetes mellitus

Autophagy in diabetes: β-cell dysfunction, insulin resistance, and complications

Dysregulation of pancreatic β-cell autophagy and the risk of type 2 diabetes

Role of β‐cell autophagy in β‐cell physiology and the development of diabetes

Mitophagy and mitochondrial dynamics in type 2 diabetes mellitus treatment

The role of autophagy in the treatment of type II diabetes and its complications: a review

Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets

Targeting Autophagy in Obesity: from Pathophysiology to Management.

5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications

The ubiquitin-proteasome system and autophagy: self-digestion for metabolic health

Pancreatic β-Cells, Diabetes and Autophagy

Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?

Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (-)-epigallocatechin-3-gallate.